Micromet GmbH (Munich) has announced that Patrick Baeuerle has joined the company as chief scientific officer and member of the executive board. Dr. Baeuerle was previously director of drug discovery at Tularik.

Lee E. Babiss has been named vice president of preclinical research and development at Hoffmann-La Roche (Nutley, NJ), succeeding Dennis Loh. Dr. Babiss joins Roche from Glaxo Wellcome, where he was most recently vice president of biological sciences.

MedImmune (Gaithersburg, MD) has announced that Melvin D. Booth has joined the company as president and chief operating officer. He is expected to be elected to the board of directors. Mr. Booth was most recently president and COO of Human Genome Sciences.

Scios (Mountain View, CA) has announced that Richard B. Brewer has been named president and CEO, following the retirement of current chairman and CEO Richard Casey as an officer and director. Mr. Brewer has also been elected a director of Scios. He is a former senior vice president at Genentech.

Scott P. Bruder has been named vice president of R&D at Anika Therapeutics (Woburn, MA). Most recently, Dr. Bruder was director of bone and soft tissue research for Osiris Therapeutics.

Theo de Roij has joined Aphton (Miami, FL) as vice president, business and product development. Dr. de Roij was most recently director, business development at SmithKline Beecham Biologicals in Belgium. Aphton also announced the appointment of Douglas A. Eayrs, of the investment firm John G. Kinnard & Co., as vice president and chief financial information officer.

Hoechst Marion Roussel (Frankfurt) has named Errol Bento De Souza head of lead generation in its drug innovation and approval organization. Dr. De Souza comes to HMR from Neurocrine Biosciences, which he co-founded in 1992, and where he served as executive vice president of R&D, CSO, and as a director.

Inhale Therapeutic Systems (San Carlos, CA) has reorganized its management to create a co-chief executive, and has named current COO Ajit Gill co-CEO. Current CEO and president Robert Chess will become co-CEO, and the post of president will be eliminated. Before joining Inhale in 1992, Gill was vice president and general manager of Kodak's Interactive Systems division. Chess has served as Inhale's president since 1991 and CEO since 1992.

Elizabeth M. Greetham has been named to the board of directors of Sequus Pharmaceuticals (Menlo Park, CA). Ms. Greetham has been an analyst with Weiss, Peck & Greer since 1990. She manages the Weiss Peck & Greer Life Sciences Funds, which invest in select biotechnology stocks.

Robert Mansfield, chief executive of Vanguard Medica Group, has been elected chairman of the Bioindustry Association (BIA; London). Mr. Mansfield takes over from John Padfield, chief executive of the Chiroscience Group, who has been BIA's chairman since 1996. In addition, BIA has named Aisling Burnand director of public affairs. Ms. Burnand was previously business group director for the Rowland Company, a London-based public affairs consultancy.

Barry G. Pea has been promoted to vice president and deputy general counsel of Immunex (Seattle, WA). Since joining the company in 1996, Mr. Pea had served as associate general counsel.

Vishva R. Rai has been named vice president of operations of the Collaborative BioAlliance (Stony Brook, NY). Dr. Rai was previously vice president of biopharmaceuticals at Hoffmann-La Roche, and was most recently vice president of operations at V.I. Technologies.

Pioneer Hi-Bred International (Des Moines, IA) has appointed Steven Rothstein research director of agronomic traits. Dr. Rothstein was previously professor and chair of the department of molecular biology and genetics at the University of Guelph in Ontario, Canada.

Geoffrey T. Yarranton has been appointed vice president, research at Coulter Pharmaceutical (Palo Alto, CA). Dr. Yarranton joins Coulter from Celletech Therapeutics, where he was most recently research director.